@article{645c9b0f196b452283bf1a6829abf9a2,
title = "Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients",
abstract = "Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.",
keywords = "JC virus, Multiple sclerosis, disease activity, natalizumab, ocrelizumab, progressive multifocal leukoencephalopathy",
author = "{van Lierop}, {Z. Y. G. J.} and Toorop, {A. A.} and Coerver, {E. M. E.} and Willemse, {E. A. J.} and Strijbis, {E. M. M.} and Kalkers, {N. F.} and B. Moraal and F. Barkhof and Teunissen, {C. E.} and J. Killestein and {van Kempen}, {Z. L. E.}",
note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Dutch MS Research Foundation [grant number 18-358f]. Publisher Copyright: {\textcopyright} The Author(s) 2021. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
doi = "10.1177/20552173211013831",
language = "English",
volume = "7",
journal = "Multiple sclerosis journal - experimental, translational and clinical",
issn = "2055-2173",
publisher = "SAGE Publications Inc.",
number = "2",
}